Table 3

Cost implications per patient per year by cost category, tumour type and country

	Breast cancer		Prostate cancer		Other solid tumours
	Denosumab	Zoledronic acid*	Denosumab	Zoledronic acid*	Denosumab	Zoledronic acid*
Austria
Cost of drugs	4823	4212	4823	4418	4823	4323
Cost of administration/management	143	514	143	540	143	528
Cost of SREs	6100	7922	10856	13239	11198	13174
Total costs	11066	12648	15821	18196	16164	18024
Total cost difference (denosumab vs ZA)	−1583 (12.5%)		−2375 (13.1%)		−1861(10.3%)
Sweden
Cost of drugs	4607	4291	4607	4501	4607	4404
Cost of administration/management	604	2143	604	2248	604	2199
Cost of SREs	2564	3330	3601	4392	4016	4725
Total costs	7775	9764	8812	11140	9228	11327
Total cost difference (denosumab vs ZA)	−1988 (20.4%)		−2328 (20.9%)		−2100 (18.5%)
Switzerland
Cost of drugs	5882	4679	5882	4908	5882	4802
Cost of administration/management	623	2041	623	2141	623	2095
Cost of SREs	11204	14550	15091	18403	17095	20112
Total costs	17709	21271	21596	25453	23600	27008
Total cost difference (denosumab vs ZA)	−3562 (16.7%)		−3857 (15.2%)		−3408 (12.6%)

*Real world data on the frequency of administration of zoledronic acid were used.
All costs are in Euros.
SRE, skeletal-related event; vs, versus; ZA, zoledronic acid.